|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Zhang W, Qi X, Li H, Yu J, Wei S,
Hao X and Ren X: Randomized study of autologous cytokine-induced
killer cell immunotherapy in metastatic renal carcinoma. Clin
Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bianconi M, Faloppi L, Loretelli C, Zizzi
A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Burattini L,
Montironi R, et al: Angiogenesis genotyping in the selection of
first-line treatment with either sunitinib or pazopanib for
advanced renal cell carcinoma. Oncotarget. 7:37599–37607.
2016.PubMed/NCBI
|
|
4
|
Buchler T, Bortlicek Z, Poprach A, Pavlik
T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K,
Slaby O, et al: Outcomes for patients with metastatic renal cell
carcinoma achieving a complete response on targeted therapy: A
Registry-based Analysis. Eur Urol. 70:469–475. 2015. View Article : Google Scholar
|
|
5
|
Fishman MN, Tomshine J, Fulp WJ and
Foreman PK: A systematic review of the efficacy and safety
experience reported for sorafenib in advanced renal cell carcinoma
(RCC) in the post-approval setting. PLoS One. 10:e01208772015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan KB, Harrop J, Reddy M, Young P,
Terrett J, Emery J, Moore G and Truneh A: Characterization of a
novel TNF-like ligand and recently described TNF ligand and TNF
receptor superfamily genes and their constitutive and inducible
expression in hemato-poietic and non-hematopoietic cells. Gene.
204:35–46. 1997. View Article : Google Scholar
|
|
7
|
Zhai Y, Yu J, Iruela-Arispe L, Huang WQ,
Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, et al:
Inhibition of angiogenesis and breast cancer xenograft tumor growth
by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer.
82:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chew LJ, Pan H, Yu J, Tian S, Huang WQ,
Zhang JY, Pang S and Li LY: A novel secreted splice variant of
vascular endothelial cell growth inhibitor. FASEB J. 16:742–744.
2002.PubMed/NCBI
|
|
9
|
Zhang N, Sanders AJ, Ye L and Jiang WG:
Vascular endothelial growth inhibitor in human cancer (Review). Int
J Mol Med. 24:3–8. 2009.PubMed/NCBI
|
|
10
|
Zhai Y, Ni J, Jiang GW, Lu J, Xing L,
Lincoln C, Carter KC, Janat F, Kozak D, Xu S, et al: VEGI, a novel
cytokine of the tumor necrosis factor family, is an angiogenesis
inhibitor that suppresses the growth of colon carcinomas in vivo.
FASEB J. 13:181–189. 1999.PubMed/NCBI
|
|
11
|
Liang PH, Tian F, Lu Y, Duan B, Stolz DB
and Li LY: Vascular endothelial growth inhibitor (VEGI; TNFSF15)
inhibits bone marrow-derived endothelial progenitor cell
incorporation into Lewis lung carcinoma tumors. Angiogenesis.
14:61–68. 2011. View Article : Google Scholar :
|
|
12
|
Yamanegi K, Kawabe M, Futani H, Nishiura
H, Yamada N, Kato-Kogoe N, Kishimoto H, Yoshiya S and Nakasho K:
Sodium valproate, a histone deacetylase inhibitor, modulates the
vascular endothelial growth inhibitor-mediated cell death in human
osteosarcoma and vascular endothelial cells. Int J Oncol.
46:1994–2002. 2015.PubMed/NCBI
|
|
13
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Vascular endothelial growth inhibitor, expression in
human prostate cancer tissue and the impact on adhesion and
migration of prostate cancer cells in vitro. Int J Oncol.
35:1473–1480. 2009.PubMed/NCBI
|
|
15
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Expression of vascular endothelial growth inhibitor
(VEGI) in human urothelial cancer of the bladder and its effects on
the adhesion and migration of bladder cancer cells in vitro.
Anticancer Res. 30:87–95. 2010.PubMed/NCBI
|
|
16
|
Zhang N, Wu P, Shayiremu D, Wu L, Shan H,
Ye L, Zhao X, Cai J, Jiang WG, Gong K, et al: Suppression of renal
cell carcinoma growth in vivo by forced expression of vascular
endothelial growth inhibitor. Int J Oncol. 42:1664–1673.
2013.PubMed/NCBI
|
|
17
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong IY, Javaid S, Wong EA, Perk S, Haber
DA, Toner M and Irimia D: Collective and individual migration
following the epithelial-mesenchymal transition. Nat Mater.
13:1063–1071. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saad S, Stanners SR, Yong R, Tang O and
Pollock CA: Notch mediated epithelial to mesenchymal transformation
is associated with increased expression of the Snail transcription
factor. Int J Biochem Cell Biol. 42:1115–1122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piva F, Giulietti M, Santoni M, Occhipinti
G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G and
Montironi R: Epithelial to mesenchymal transition in renal cell
carcinoma: Implications for cancer therapy. Mol Diagn Ther.
20:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee
JM: Characterization of cis-regulatory elements of the vascular
endothelial growth inhibitor gene promoter. Biochem J. 388:913–920.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haridas V, Shrivastava A, Su J, Yu GL, Ni
J, Liu D, Chen SF, Ni Y, Ruben SM, Gentz R, et al: VEGI, a new
member of the TNF family activates nuclear factor-kappa B and c-Jun
N-terminal kinase and modulates cell growth. Oncogene.
18:6496–6504. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho QT and Kuo CJ: Vascular endothelial
growth factor: Biology and therapeutic applications. Int J Biochem
Cell Biol. 39:1349–1357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Byles V, Zhu L, Lovaas JD, Chmilewski LK,
Wang J, Faller DV and Dai Y: SIRT1 induces EMT by cooperating with
EMT transcription factors and enhances prostate cancer cell
migration and metastasis. Oncogene. 31:4619–4629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Imanaka N, Chen J and Griffin JD:
Hypoxia potentiates Notch signaling in breast cancer leading to
decreased E-cadherin expression and increased cell migration and
invasion. Br J Cancer. 102:351–360. 2010. View Article : Google Scholar :
|
|
27
|
Sato F, Kubota Y, Natsuizaka M, Maehara O,
Hatanaka Y, Marukawa K, Terashita K, Suda G, Ohnishi S, Shimizu Y,
et al: EGFR inhibitors prevent induction of cancer stem-like cells
in esophageal squamous cell carcinoma by suppressing
epithelial-mesenchymal transition. Cancer Biol Ther. 16:933–940.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiao L, Li DD, Yang CL, Peng RQ, Guo YQ,
Zhang XS and Zhu XF: Reactive oxygen species mediate
oxaliplatin-induced epithelial-mesenchymal transition and invasive
potential in colon cancer. Tumour Biol. 37:8413–8423. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang B, Zheng W, Fang L, Wu L, Zhou F,
Yin X, Yu X and Zou Z: Overexpressed targeting protein for Xklp2
(TPX2) serves as a promising prognostic marker and therapeutic
target for gastric cancer. Cancer Biol Ther. 17:824–832. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Krantz SB, Shields MA, Dangi-Garimella S,
Munshi HG and Bentrem DJ: Contribution of epithelial-to-mesenchymal
transition and cancer stem cells to pancreatic cancer progression.
J Surg Res. 173:105–112. 2012. View Article : Google Scholar :
|
|
31
|
Zhang L, Huang G, Li X, Zhang Y, Jiang Y,
Shen J, Liu J, Wang Q, Zhu J, Feng X, et al: Hypoxia induces
epithelial-mesenchymal transition via activation of SNAI1 by
hypoxia-inducible factor-1α in hepatocellular carcinoma. BMC
Cancer. 13:1082013. View Article : Google Scholar
|
|
32
|
Chu CY, Jin YT, Zhang W, Yu J, Yang HP,
Wang HY, Zhang ZJ, Liu XP and Zou Q: CA IX is upregulated in
CoCl2-induced hypoxia and associated with cell invasive
potential and a poor prognosis of breast cancer. Int J Oncol.
48:271–280. 2016.
|
|
33
|
Lombaerts M, van Wezel T, Philippo K,
Dierssen JW, Zimmerman RM, Oosting J, van Eijk R, Eilers PH, van de
Water B, Cornelisse CJ, et al: E-cadherin transcriptional
downregulation by promoter methylation but not mutation is related
to epithelial-to-mesenchymal transition in breast cancer cell
lines. Br J Cancer. 94:661–671. 2006.PubMed/NCBI
|
|
34
|
Natalwala A, Spychal R and Tselepis C:
Epithelial-mesenchymal transition mediated tumourigenesis in the
gastrointestinal tract. World J Gastroenterol. 14:3792–3797. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gilles C, Polette M, Zahm JM, Tournier JM,
Volders L, Foidart JM and Birembaut P: Vimentin contributes to
human mammary epithelial cell migration. J Cell Sci. 112:4615–4625.
1999.PubMed/NCBI
|
|
37
|
Mendez MG, Kojima S and Goldman RD:
Vimentin induces changes in cell shape, motility, and adhesion
during the epithelial to mesenchymal transition. FASEB J.
24:1838–1851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar
|
|
39
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
40
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
41
|
Kwon YJ, Baek HS, Ye DJ, Shin S, Kim D and
Chun YJ: CYP1B1 enhances cell proliferation and metastasis through
induction of EMT and activation of Wnt/β-catenin signaling via Sp1
upregulation. PLoS One. 11:e01515982016. View Article : Google Scholar
|
|
42
|
Lee SC, Kim OH, Lee SK and Kim SJ: IWR-1
inhibits epithelial-mesenchymal transition of colorectal cancer
cells through suppressing Wnt/β-catenin signaling as well as
survivin expression. Oncotarget. 6:27146–27159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ai R, Sun Y, Guo Z, Wei W, Zhou L, Liu F,
Hendricks DT, Xu Y and Zhao X: NDRG1 overexpression promotes the
progression of esophageal squamous cell carcinoma through
modulating Wnt signaling pathway. Cancer Biol Ther. 17:943–954.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bolós V, Peinado H, Pérez-Moreno MA, Fraga
MF, Esteller M and Cano A: The transcription factor Slug represses
E-cadherin expression and induces epithelial to mesenchymal
transitions: A comparison with Snail and E47 repressors. J Cell
Sci. 116:499–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Storci G, Sansone P, Trere D, Tavolari S,
Taffurelli M, Ceccarelli C, Guarnieri T, Paterini P, Pariali M,
Montanaro L, et al: The basal-like breast carcinoma phenotype is
regulated by SLUG gene expression. J Pathol. 214:25–37. 2008.
View Article : Google Scholar
|
|
46
|
Hajra KM, Chen DY and Fearon ER: The SLUG
zinc-finger protein represses E-cadherin in breast cancer. Cancer
Res. 62:1613–1618. 2002.PubMed/NCBI
|
|
47
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
